Literature DB >> 3684202

Prognostic factors in the uveitis of juvenile rheumatoid arthritis.

M D Wolf1, P R Lichter, C G Ragsdale.   

Abstract

Risk factors for significant visual loss were investigated in 51 patients with iridocyclitis associated with juvenile rheumatoid arthritis (JRA). Average follow-up was 12.7 years. Of 89 eyes with uveitis, 22% had visual loss to 20/200 or worse, 46% had cataracts, 30% had band keratopathy, and 27% had glaucoma. Severity of visual loss and complications correlated with the degree of inflammation found on initial ocular examination. Of 58 eyes that were initially normal or had signs of mild inflammation (cells, flare, keratitic precipitates), 3% had final vision of 20/200 or worse, 28% had cataracts, 5% had band keratopathy, and 17% had glaucoma. Of 31 eyes with posterior synechiae on initial examination, 58% had final vision of 20/200 or worse, 81% had cataracts, 77% had band keratopathy, and 45% had glaucoma. When arthritis clearly preceded uveitis, 6% of patients had a poor visual outcome compared to 67% of patients whose initial manifestation of JRA was uveitis. Systemic corticosteroid administration used primarily for arthritis correlated with cataract formation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3684202     DOI: 10.1016/s0161-6420(87)80007-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  34 in total

Review 1.  Uveitis in juvenile idiopathic arthritis.

Authors:  Arnd Heiligenhaus; Kirsten Minden; Dirk Föll; Uwe Pleyer
Journal:  Dtsch Arztebl Int       Date:  2015-02-06       Impact factor: 5.594

2.  [Vision-threatening complications in childhood uveitis].

Authors:  A Mingels; T Hudde; C Heinz; A Heiligenhaus
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

3.  Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis.

Authors:  Fasika Woreta; Jennifer E Thorne; Douglas A Jabs; Sanjay R Kedhar; James P Dunn
Journal:  Am J Ophthalmol       Date:  2006-12-20       Impact factor: 5.258

4.  Lensectomy for complicated cataract in juvenile chronic iridocyclitis.

Authors:  J J Kanski
Journal:  Br J Ophthalmol       Date:  1992-02       Impact factor: 4.638

5.  An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood.

Authors:  Clive Edelsten; Vickie Lee; Christopher R Bentley; Jack J Kanski; Elizabeth M Graham
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

Review 6.  [Uveitis in conjunction with rheumatological diseases in childhood].

Authors:  C Sengler; R Keitzer; U Pleyer
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

7.  Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study.

Authors:  Anthony C Gregory; John H Kempen; Ebenezer Daniel; R Oktay Kaçmaz; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne
Journal:  Ophthalmology       Date:  2012-10-11       Impact factor: 12.079

8.  Juvenile idiopathic arthritis-associated uveitis: Data from a region in western Greece.

Authors:  Ioannis Asproudis; Taxiarchis Felekis; Elena Tsanou; Spiridon Gorezis; Eikaterini Karali; Sapfo Alfantaki; Antigoni Siamopoulou-Mauridou; Miltiadis Aspiotis
Journal:  Clin Ophthalmol       Date:  2010-04-26

9.  Uveitis and juvenile idiopathic arthritis: A cohort study.

Authors:  David BenEzra; Evelyne Cohen; Francine Behar-Cohen
Journal:  Clin Ophthalmol       Date:  2007-12

10.  Adalimumab for juvenile idiopathic arthritis-associated uveitis.

Authors:  Adriano Magli; Raimondo Forte; Pasqualina Navarro; Giustina Russo; Francesca Orlando; Loredana Latanza; Maria Alessio
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-01       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.